

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

TAUNS Laboratories, Inc.

Announcement of Participation in the Triple I for Global Health
(Impact Investment Initiative for Global Health)

IZUNOKUNI, Japan, October 31, 2024 - TAUNS Laboratories, Inc. (Headquarters: Izunokuni-shi, Shizuoka, Japan; President and CEO: Masaki Nonaka; Securities Code: 197A; hereinafter referred to as "the Company") announces that it has recently joined the Triple I for Global Health (Impact Investment Initiative for Global Health, hereinafter referred to as "Triple I").

Triple I is an initiative endorsed at the G7 Hiroshima Summit 2023 which aims at addressing global health issues in LMICs through mobilizing private capital by impact investments.

With the corporate slogan "Peace of mind through diagnostic technology," the Company is promoting "Contributions to Global Health" as one of the material issues that the Company prioritizes in its ESG (environment, society, governance) initiatives.

The Company's tuberculosis diagnostic kit, Capilia TB, was endorsed by the World Health Organization (WHO) in 2007, and its successor, Capilia TB-Neo, in 2012. In the diagnosis of tuberculosis, we have been working towards a TB-free world by collaborating with the United Nations Office for Project Services (UNOPS) and Stop TB Partnership's Global Drug Facility (GDF). Capilia TB-Neo is now listed in the "Diagnostics, Medical Devices & Other Health Products Catalog" of Stop TB Partnership's GDF, as well as in the "List of TB diagnostic test kits and equipments classified according to the Global Fund Quality Assurance Policy" of The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund). In addition, Capilia TB-Neo is described in the "Product Catalogue for Solutions to Global Health Challenges" (published in October 2024) edited by the Ministry of Health, Labour and Welfare of Japan to introduce Japanese products that contribute to solving global health issues.

By participating in Triple I, the Company aims to make an even greater contribution to solving social issues. Utilizing the proprietary technologies we have developed over 30 years, we continue creating in vitro diagnostics that support global health, and engage in improving their quality, so that we will contribute to shaping a more sustainable world by helping ensure healthier lives for all at all ages.

About TAUNS:

TAUNS Laboratories, Inc. is one of the major companies of rapid diagnostic test kits for infectious diseases

in Japan. We manufacture in vitro diagnostic test kits and research reagents applying various diagnostic technologies for global consumption. In the field of rapid diagnostic test kits for infectious diseases, which are our main products, we have been widely known for high-quality products and customer services by hospitals, clinics, research institutes and biotech start-ups. For over 30 years since the Company was established in 1987, under the corporate philosophy of enriching lives and providing peace of mind, we have strived to develop and improve our products. As a leading company of rapid diagnostic test kits in Japan, we continue to advance R&D to meet the needs for clinical tests. For more information, please visit our website at <https://www.tauns.co.jp/en/>.

Related URL:

- About Triple I for Global Health

<https://tripleiforgh.org/>

- TAUNS' initiatives to the "Contributions to Global Health"

<https://www.tauns.co.jp/en/sustainability/globalhealth/>

The purpose of this release is to provide our stakeholders with the latest information related to our companies. Although it may contain information on our products and research and development, it is intended to disclose our management information and is not intended as promotion, advertisement, or medical advice regarding our products.

For inquiries regarding this press release, please contact:

TAUNS Laboratories, Inc.

General Affairs Department

TEL: +81-55-957-3090

E-mail: kouhou@tauns.co.jp